34results about How to "Inhibition of expression" patented technology

The invention discloses a drug for preventing and treating atherosclerotic plaque by adopting methods for removing wind, expelling phlegm and detoxifying, and a preparation method of the drug. The product formula comprises the following raw materials by weight: 3-5g of scorpio, 2-4g of centipede, 10-15g of earthworm, 10-15g of leech, 10-15g of pericarpium citri reticulatae, 10-15g of pinellia ternate, 10-15g of bighead atractylodes rhizome and 10-15g of honeysuckle. The preparation method comprises the following steps: soaking the scorpio, the centipede, the earthworm, the leech, the pericarpium citri reticulatae, the pinellia ternate, the bighead atractylodes rhizome and the honeysuckle for 40 minutes by 15-fold water; decocting by a slow fire for 70 minutes for the first time; adding 10fold water to decoct by the slow fire for 50 minutes for the second time; adding 6-fold water to decoct by the slow fire for 30 minutes for the third time; merging the decocted liquors of three times; filtering the obtained liquor by a gauze; concentrating by a water bath at 100 DEG C into 200ml of liquor after filtering, so as to obtain the product. The drug disclosed by the invention is simple in component, accurate in compatibility relationship, few in drugs, low in price, and accurate and significant in curative effect. The animal experiment proves that the drug has significant effects of preventing and treating arteriosclerosis, and adjusting blood fat, and is easily accepted by a sufferer.

The invention relates to the technical field of medicines, discloses a preparation method of a phenylpropanoid compound, and particularly relates to a phenylpropanoid compound which is obtained by being separated from dried roots of moghania macrophylla (Willd.) O Ktze.. The phenylpropanoid compound is prepared through the steps of solvent extraction, column chromatographic separation and liquid phase preparation, separation and purification. The phenylpropanoid compound obtained through the method is reported for the first time and is high in purity. It is proved through experiments that the obtained novel phenylpropanoid compound can inhibit expression effects of cell inflammatory factors of TNF-alpha, IL-1 beta and IL-6, has an inhibiting effect on hydroxyl free radicals (-OH), has anti-inflammatory and antioxidant activities, is beneficial for treatment of various inflammatory diseases such as cervicitis, endometritis, pelvic inflammation, mastitis, faucitis and / or arthritis and can be developed into a novel drug. The compound is the phenylpropanoid compound with the structural formula as shown in a formula (I) and pharmaceutically acceptable salts thereof. Please see the formula (I) in the description.

The invention relates to a siRNA molecule for interfering the expression of a Bcl-2 gene and application thereof. The positive chain of the siRNA molecule is SEQ ID NO:1, and the negative chain is SEQ ID NO:2, wherein the negative chain can be specifically combined with the mRNA of the Bcl-2 gene to degrade the mRNA so as to interfere a translation process after interference transcription and achieve the purpose of resisting tumors.

The invention relates to the technical field of medicines, discloses a phenylpropanoid compound preparation method and particularly relates to a phenylpropanoid compound separated from dry roots of Moghania macrophylla (Willd.) O.Ktze.. The phenylpropanoid compound is obtained by solvent extraction, column chromatography separation and preparative liquid phase separation and purification. The phenylpropanoid compound prepared by the preparation method is put forward for the first time and is high in purity.Experiments prove that the novel phenylpropanoid compound is capable of inhibiting content of inflammatory cytokines NO and expression of inflammatory cytokines TNF (tumor necrosis factor)-alpha and plays a role in inhibiting hydroxyl radicals (-OH) to further have anti-inflammatory effect and antioxidant activity and benefit treatment of various inflammatory diseases such as cervicitis, endometritis, pelvic inflammation, mastitis, sphagitis and / or arthritis, thereby being developed into novel medicines. The phenylpropanoid compound shown as structural formula (I) and pharmaceutically acceptable salts thereof are prepared.

The invention relates to the technical field of drugs, and discloses an application of phenylpropanoids compounds and pharmaceutically acceptable salts in preparation of drugs for treating inflammation diseases. The phenylpropanoids compounds can inhibit the content of a cell inflammatory factor NO, inhibits expressive effects of cell inflammatory factors TNF-alpha, IL-1beta and IL-6, has an inhibition effect on hydroxyl radicals (-OH), has anti-inflammatory and antioxidant activities, and provides a direction for development of the drugs for treating inflammation diseases, such as cervicitis, endometritis, pelvic inflammatory disease, mastitis, pharyngolaryngitis and / or arthritis and other diseases.

The invention relates to the technical field of medicine, and discloses application of a phenylpropanoid compound and medically-acceptable salt thereof in preparing medicine for treating inflammatory diseases. The phenylpropanoid compound shows the effect of inhibiting expression of inflammatory cytokines TNF-alpha, IL-1beta and IL-6 and has an inhibiting effect on hydroxyl radicals (-OH), and thus the phenylpropanoid compound has anti-inflammatory activity and anti-oxidative activity and provides direction for development of medicine for treating inflammatory diseases such as cervicitis, endometritis, pelvic inflammation, mastitis, sphagitis and / or arthritis.